Dahlin Maria, Stödberg Tommy, Ekman Elin, Töhönen Virpi, Wedell Anna
Neuropaediatric Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm 171 77, Sweden.
Neuropediatric Department, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm 171 76, Sweden.
Brain Commun. 2025 Apr 5;7(2):fcaf134. doi: 10.1093/braincomms/fcaf134. eCollection 2025.
A ketogenic diet is used in children with drug-resistant epilepsy but predictors for efficacy are largely lacking. Our aim was to evaluate if causative genetic variants could predict seizure response to the ketogenic diet. A cohort study of 226 children with refractory epilepsy and classic ketogenic diet treatment for at least 3 months (76.9% of the 294 who started) was performed. The median age at diet start was 5.1 years (range 0.1-17.8), 118 were girls and 108 boys. They had previous trials of a median of 6.0 anti-seizure medications (range 0-12) and intellectual disability was found in 87%. Seizure response (≥50% reduction) was found in 138/226 patients (61.1%) at 3 months, 121 (53.5%) at 6 months, 107 (47.3%) at 1 year and in 80 (37.0%) at 2 years follow-up of ketogenic diet. Age of epilepsy onset was lower and combined epilepsy type less common in responders compared to non-responders but no differences were found for specific seizure types, ketogenic ratio or beta-hydroxybutyric acid blood levels. A causative pathogenic/likely pathogenic variant was detected in 107/153 = 69.9% in 48 different genes. Next generation sequencing was used in 91/226 (40%) cases with a diagnostic yield of 58.2% (53/91). In comparison with cases without a revealed genetic aetiology, patients with a causative genetic variant had less atonic seizures and epileptic spasms and a better seizure response with 17.3% seizure free and 25% with >90% seizure reduction at 2-year follow-up. Causative variants in , , and showed significant diet response ( < 0.05) and good efficacy was also associated with , , , , and . Causative variants in and were among genes linked to a lack of response. To our knowledge not described previously, we report a good ketogenic diet response related to causative variants in , , , , , , and but a lack of response for causative variants in , , , , , , , and After grouping of genes into functional groups, causative variants in transporter genes had the best response ( = 0.009) and variants in other membrane-related proteins (ion channels and neurotransmitter receptors) also showed good efficacy. However, the gene group related to cell structural integrity and/or homeostasis had the worst diet response ( = 0.00006). In conclusion, our results support that causative genetic variants may be used as prognostic markers of ketogenic diet response, constituting an example in the expanding area of precision medicine.
生酮饮食用于治疗耐药性癫痫患儿,但在很大程度上缺乏疗效预测指标。我们的目的是评估致病基因变异是否可以预测生酮饮食的癫痫发作反应。对226例难治性癫痫患儿进行了队列研究,这些患儿接受经典生酮饮食治疗至少3个月(占开始治疗的294例患儿的76.9%)。开始饮食时的中位年龄为5.1岁(范围0.1 - 17.8岁),女孩118例,男孩108例。他们之前平均尝试过6.0种抗癫痫药物(范围0 - 12种),87%的患儿存在智力残疾。生酮饮食3个月时,138/226例患者(61.1%)出现癫痫发作反应(减少≥50%),6个月时为121例(53.5%),1年时为107例(47.3%),2年随访时为80例(37.0%)。与无反应者相比,有反应者的癫痫发病年龄更低,合并癫痫类型更少见,但在特定癫痫类型、生酮比例或血β - 羟基丁酸水平方面未发现差异。在48个不同基因中,107/153 = 69.9%检测到致病的致病/可能致病变异。91/226(40%)例使用了二代测序,诊断率为58.2%(53/91)。与未揭示遗传病因的病例相比,有致病基因变异的患者失张力发作和癫痫痉挛较少,癫痫发作反应更好,2年随访时17.3%无癫痫发作,25%癫痫发作减少>90%。、、和中的致病变异显示出显著的饮食反应(<0.05),良好疗效也与、、、、和相关。和中的致病变异属于与无反应相关的基因。据我们所知,此前未被描述过,我们报告了与、、、、、、和中的致病变异相关的良好生酮饮食反应,但、、、、、、、和中的致病变异无反应。将基因分组为功能组后,转运蛋白基因中的致病变异反应最佳(=0.009),其他膜相关蛋白(离子通道和神经递质受体)中的变异也显示出良好疗效。然而,与细胞结构完整性和/或内环境稳定相关的基因组饮食反应最差(=0.00006)。总之,我们的结果支持致病基因变异可作为生酮饮食反应的预后标志物,这是精准医学不断拓展领域中的一个实例。
Eur J Paediatr Neurol. 2015-1
Cochrane Database Syst Rev. 2020-6-24
Pediatr Neurol. 2016-11
JAMA Netw Open. 2023-7-3
Orphanet J Rare Dis. 2022-12-5